Prognostic significance of MSI2 predicts unfavorable outcome in adult B-acute lymphoblastic leukemia
Prognostic significance of MSI2 predicts unfavorable outcome in adult B-acute lymphoblastic leukemia
复制标题
DOI：
10.1111/ijlh.12284
复制
发表时间：
2015-04-01
影响因子：
3
通讯作者：
Ghazy, H. F.
中科院分区：
文献类型：
--
作者：
Aly, R. M.;Ghazy, H. F.
Musashi-2基因（MSI 2）与白血病的发生有关，MSI 2的高表达与急性髓细胞白血病（AML）和急性淋巴细胞白血病（ALL）的生存率降低有关，提示其可作为一种新的预后标志物。方法采用实时荧光定量聚合酶链反应（PCR）技术检测140例成人B-ALL患者及对照组中MSI 2的表达水平。MSI 2高表达与患者的临床特征无关。然而，MSI 2高表达的患者完全缓解（CR）的发生率显著较低（P=0.03），总生存期较差（P=0.018），无病生存期较短（P=0.001）。多因素分析显示，高MSI 2表达是一个独立的预后因素为成人BCR-ABL 1阴性B-ALL patients.ConclusionThese结果证实了与成人B-ALL的结果MSI 2表达的关联，并证明MSI 2作为一个临床预后生物标志物的效用。
IntroductionThe Musashi-2 gene (MSI2) is implicated in leukemogenesis, and high MSI2 expression has been associated with decreased survival in acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL), suggesting its use as a new prognostic marker. We aimed to validate the prognostic significance of MSI2 in ALL.MethodsMSI2 expression was measured by real-time polymerase chain reaction in 140 adult B-ALL patients and compared to controls.ResultsMSI2 expression level in patients was significantly higher when compared to the control group (P=0.001). High MSI2 expression did not correlate with the clinical characteristics of patients. However, patients with high MSI2 expression had significantly lower incidence of complete remission (CR) (P=0.03), inferior overall survival (P=0.018), and shorter disease-free survival (P=0.001). Multivariate analysis revealed that high MSI2 expression was an independent prognostic factor for adult BCR-ABL1-negative B-ALL patients.ConclusionThese results confirm the association of MSI2 expression with outcome in adult B-ALL and demonstrate the utility of MSI2 as a clinical prognostic biomarker.